health.economictimes.indiatimes.com Open in urlscan Pro
2a02:26f0:64:6a2::3126  Public Scan

Form analysis
4 forms found in the DOM

<form>
  <ul class="consent-list">
    <li>
      <input type="checkbox" id="id_analytics" onclick="analyticsCookie(this)">
      <label for="id_analytics"> Analytics and Performance Cookies <img width="14" height="14" src="https://st.etb2bimg.com/Themes/Release/theme4/images/icons/icon_info_circle.svg" alt="">
      </label>
    </li>
    <li>
      <input type="checkbox" id="id_advertising" name="">
      <label for="id_advertising"> Targeted and Advertising Cookies <img width="14" height="14" src="https://st.etb2bimg.com/Themes/Release/theme4/images/icons/icon_info_circle.svg" alt="">
      </label>
    </li>
    <input id="gdpr_consent" class="btn" type="button" value="I Accept">
  </ul>
</form>

<form class="hide">
  <input name="config.optout" type="checkbox" value="1" checked="">
  <input name="config.PHPSESSID" type="checkbox" value="1" checked="">
  <input name="config.accessCode" type="checkbox" value="1" checked="">
  <input name="config.pfuuid" type="checkbox" value="1" checked="">
  <input name="config.OSTID " type="checkbox" value="1" checked="">
  <input name="config.OSSOID" type="checkbox" value="1" checked="">
  <input name="config.OSTPID" type="checkbox" value="1" checked="">
  <input name="config.fpid" type="checkbox" value="1" checked="">
  <input type="checkbox" name="useragreement" checked="" value="1">
  <div id="data-analytics">
    <input class="analytics-data" name="config.ga" value="0" checked="">
    <input class="analytics-data" name="config.ibeat" value="0" checked="">
    <input class="analytics-data" name="config.growthrx" value="0" checked="">
  </div>
</form>

GET https://health.economictimes.indiatimes.com/search

<form method="get" class="top-panel__search--form" id="search_form" action="https://health.economictimes.indiatimes.com/search">
  <input name="q" aria-label="Query" type="text" class="top-panel__search--input" autocomplete="off" placeholder="Search" value="">
</form>

#

<form action="#" class="top-newsletter-subs__form">
  <label for="nl_input_box" aria-hidden="true" class="hide">Enter Email</label>
  <input type="text" id="subscribe_email_top" placeholder="Your Email" class="input-box top-newsletter-subs__input-box">
  <div id="subcribe_response_top" class="et-rtl-error"></div>
  <input id="subscriber_btn_top" type="button" value="Subscribe For Free" onclick="EtB2b.subscription.updateSubscription('top');" class="btn top-newsletter-subs__submit btn-variation">
</form>

Text Content

X


WE USE COOKIES TO ENSURE BEST EXPERIENCE FOR YOU

We use cookies and other tracking technologies to improve your browsing
experience on our site, show personalize content and targeted ads, analyze site
traffic, and understand where our audience is coming from. You can also read our
privacy policy, We use cookies to ensure the best experience for you on our
website.


BY CHOOSING I ACCEPT, OR BY CONTINUING BEING ON THE WEBSITE, YOU CONSENT TO OUR
USE OF COOKIES AND TERMS & CONDITIONS.

 * Analytics and Performance Cookies
 * Targeted and Advertising Cookies
   


Login

Get App
 * 
 * News
   HospitalsM&AResearchFinancePharmaMedical
   DevicesDiagnosticsPolicyIndustryPeople MovementSlideshows
   Show All News
   
 * Exclusives
 * Leaders Speak
 * Events
 * Awards
 * Webinars
 * More
   Newsletters MasterClasses About Us Contact Us Advertise With Us


Search
Pharma Policy Medical Devices Diagnostics Industry Hospitals
 * More


INDIA DIAGNOSTICS SUMMIT


INDIA DIAGNOSTIC SUMMIT - INDIA DIAGNOSTIC EVENT & CONFERENCE PROVIDES A
PLATFORM IN THE DIAGNOSTIC SECTOR WITH ENHANCED BUSINESS OPPORTUNITIES. THE
DIAGNOSTICS EVENTS PLATFORM CAN HELP YOU REACH MORE CLIENTS AND KNOWLEDGE, TO
ATTAIN BUSINESS GROWTH


MASTERCLASS


MARSHALL GOLDSMITH & R. GOPALAKRISHNAN ON LEADERSHIP DEVELOPMENT & STRATEGIC
INNOVATION


 * PFIZER BEATS PROFIT ESTIMATES ON DEMAND FOR NEW DRUGS, COVID PRODUCTS
   
   
   ANTIVIRAL TREATMENT PAXLOVID SALES CAME IN AT $4.07 BILLION, ALSO BEATING
   ESTIMATES OF $3.13 BILLION. THE COMPANY EXPECTING SIGNIFICANTLY LOWER SALES
   CONTRIBUTIONS FROM COVID PRODUCTS IN THE SECOND QUARTER FROM THE FIRST
   QUARTER. EXCLUDING COVID PRODUCTS, PFIZER SAID FIRST-QUARTER REVENUE WAS
   MOSTLY DRIVEN BY RECENTLY ACQUIRED PRODUCTS, INCLUDING MIGRAINE DRUG NURTEC
   ODT AND SICKLE CELL DISEASE TREATMENT OXBRYTA.


 * UNDERSTANDING GENETIC DETERMINANTS CAN IMPROVE MULTIDIMENSIONAL ASPECTS OF
   ASTHMA
   
    * Exclusive


 * AIIMS DELHI TO CREATE DASHBOARDS FOR ACCOMMODATION ALLOTMENT, GUEST HOUSE
   BOOKING


 * OCCLUDIN PROTEIN IN HUMANS FOUND TO HELP IN CORONAVIRUS TRANSMISSION BETWEEN
   CELLS


 * US FDA HALTS SUN PHARMA'S TRIALS ON DERMATOLOGICAL DRUG

View More
Latest Most Read


 * DUPONT TO BUY SPECTRUM PLASTICS GROUP FOR $1.75 BILLION


 * DELHI HC ALLOWS MINOR TO MEDICALLY TERMINATE 11 WEEKS PREGNANCY


 * 2-MONTH-OLD CHILD DIAGNOSED WITH RARE YEAST INFECTION GETS NEW LEASE OF LIFE
   AT NOIDA HOSPITAL


 * NEWLY-DEVELOPED CENSOR CAN DETECT EARLY SIGNS OF CANCER, DISTINGUISH TYPE OF
   TUMOURS: STUDY


 * ELANCO'S THERAPY FOR CANINE PARVOVIRUS GETS FIRST NOD


 * DR DANGS LAB LAUNCHES AI-POWERED NOVEL TEST FOR ALLERGIES 'ALLERGYNIUS DX'


 * ONCOLOGY DRUG SALES TO GENERATE $2.2 TRILLION BETWEEN 2023 AND 2029:
   GLOBALDATA


 * MOLECULAR, PRECISION MEDICINE SHOWING HUGE HOPE IN CANCER TREATMENT: DR HARIT
   K CHATURVEDI
   
    * Exclusive

View More


 * DRUG DUPLICATED TO DEFAME INDIA PHARMA CO CHIEF ON WHO ALERT


 * GSK LAUNCHES ANTI-SHINGLES VACCINE IN INDIA


 * FIRST PILL FOR FECAL TRANSPLANTS WINS FDA APPROVAL


 * START-UPS CAN RAMP UP THE MENTAL HEALTH ECOSYSTEM IN INDIA


 * PM MODI TO INAUGURATE 'ONE EARTH ONE HEALTH' ADVANTAGE HEALTHCARE INDIA -2023


 * AYURVED DOCTORS NOT ENTITLED TO SAME SALARY AS THAT OF MBBS COUNTERPARTS: SC


 * WORLD'S FIRST 'GENE SILENCING' ALZHEIMER'S DRUG SHOWS PROMISE


 * THE NEW NATIONAL MEDICAL DEVICE POLICY WILL MAKE INDIA SELF-SUFFICIENT IN THE
   MEDTECH MARKET: EXPERTS
   
    * Exclusive


 * CHINA'S COVID COVER-UP HAD HUGE HELP FROM WESTERN ELITES: REPORT

Advertisement


Advertisement







STAY UPDATED & MAKE INFORMED DECISIONS

Get latest top stories from across industry curated by our editors.

Get latest top stories from across industry curated by our editors.

Enter Email



DOWNLOAD ETHEALTHWORLD APP FOR REALTIME UPDATES OF CONTENT YOU FOLLOW

 * Seamless reading experience
 * Save your favourite articles









PHARMA


 * ELANCO'S THERAPY FOR CANINE PARVOVIRUS GETS FIRST NOD
   
   Elanco's therapy belongs to a class of treatments known as monoclonal
   antibodies and is a one-shot intravenous treatment. It is the company's first
   monoclonal antibody therapy. The treatment can be administered to dogs eight
   weeks of age or older with canine parvovirus by a veterinarian, providing a
   more effective solution than supportive care alone.
   
   
   ELANCO'S THERAPY FOR CANINE PARVOVIRUS GETS FIRST NOD
   
   Elanco's therapy belongs to a class of treatments known as monoclonal
   antibodies and is a one-shot intravenous treatment. It is the company's first
   monoclonal antibody therapy. The treatment can be administered to dogs eight
   weeks of age or older with canine parvovirus by a veterinarian, providing a
   more effective solution than supportive care alone.


 * PFIZER BEATS PROFIT ESTIMATES ON DEMAND FOR NEW DRUGS, COVID PRODUCTS


 * ONCOLOGY DRUG SALES TO GENERATE $2.2 TRILLION BETWEEN 2023 AND 2029:
   GLOBALDATA


 * GILEAD, US SQUARE OFF IN BILLION-DOLLAR HIV DRUG PATENT TRIAL


 * US FDA HALTS SUN PHARMA'S TRIALS ON DERMATOLOGICAL DRUG


 * BIOPHARMA FIRM ACELYRIN SEEKS $1.5 BLN VALUATION IN US IPO


 * US FDA DECLINES TO APPROVE ASCENDIS' HORMONE DISORDER THERAPY


 * WHAT'S BEHIND SHORTAGES OF ADDERALL, OZEMPIC AND OTHER MEDS?


 * COSTA RICAN SLOTH ANTIBIOTICS OFFER HOPE FOR HUMAN MEDICINE


 * SAFE PHARMA DEREGISTERED FOR SMUGGLING PSYCHOTROPIC DRUG TO SUDAN


 * JAPAN'S ASTELLAS PHARMA AGREES TO BUY IVERIC BIO FOR $5.9 BLN


 * SPURT IN DEMAND FOR NON-COVID VACCINES IN KOLKATA


 * PFIZER, BIONTECH PROPOSE EU PAYS HALF FOR EACH CANCELLED COVID DOSE: REPORT

View More


INTERVIEWS

 *  * Exclusive
   
   
   MOLECULAR, PRECISION MEDICINE SHOWING HUGE HOPE IN CANCER TREATMENT: DR HARIT
   K CHATURVEDI
   
   If you look at the detection rate and at what stage people got diagnosed with
   cancer, it was all stages three and four previously. Today the number has
   shifted to a significant extent in India and about 30-40 per cent of people
   now come in stages one and two, which is significantly better.
   
    * Exclusive
   
   
   MOLECULAR, PRECISION MEDICINE SHOWING HUGE HOPE IN CANCER TREATMENT: DR HARIT
   K CHATURVEDI
   
   If you look at the detection rate and at what stage people got diagnosed with
   cancer, it was all stages three and four previously. Today the number has
   shifted to a significant extent in India and about 30-40 per cent of people
   now come in stages one and two, which is significantly better.


 * IN ORTHOPAEDIC SPORTS MEDICINE, MOST OF THE PROBLEMS ARE TREATED
   ARTHROSCOPICALLY: PROF. C NIEK VAN DIJK, FIFA MEDICAL CENTRE OF EXCELLENCE,
   MADRID


 * WITH AI AT HAND, A NEW ERA OF STILL SAFER ANAESTHESIA IS JUST AROUND THE
   CORNER: DR. NAMITA SHARMA


 * HYPER-LOCAL MARKETS REPRESENT GROWTH MARKETS FOR INDIAN PHARMACEUTICAL
   COMPANIES


 * ONLY WHEN SUPPLY CHAINS ARE IMPROVED AND PPP IS PROACTIVE WILL MALARIA BE
   COMPLETELY ERADICATED: PRATIK KUMAR, MALARIA NO MORE


 * ALL LIVING DONOR TRANSPLANTS WILL BE DONE BY ROBOTIC SURGERY IN NEAR FUTURE:
   DR ARVINDER SOIN
   
    * Exclusive


 * PRIMARY HEALTHCARE REQUIRES LONG-TERM INVESTMENT, BUT QUICK RETURNS SHOULD
   NOT BE EXPECTED: DIAH SAMINARSIH, FOUNDER & CEO, CISDI


 * NEW PRODUCTS IN ONCOLOGY SPACE WILL CONTINUE TO BE OUR GROWTH DRIVERS: DR
   ANIL KUKREJA, ASTRAZENECA INDIA
   
    * Exclusive


 * POST-COVID FATIGUE IS THE LIKELY OUTCOME OF A REDUCTION IN CONNECTIVITY
   BETWEEN THE NERVE CELLS IN THE BRAIN: PROF. MARTIN SCHALLING, KAROLINSKA
   INSTITUTET


 * WITH A LOT OF DATA FLOWING IN TO TRAIN THE POWERFUL AI AND ML MODELS, WE WILL
   NEED A GOOD DATA SECURITY FRAMEWORK: ALESSANDRO DAVIDE IALONGO, CO-FOUNDER,
   EVEN HEALTHCARE


 * COLLABORATIONS AND SURVEILLANCE ARE GOING TO BE THE KEY FOR US TO BE PREPARED
   FOR THE NEXT PANDEMIC: NEERAJ JAIN, PATH


 * GREATEST ADVANTAGE OF PROTON THERAPY IS ITS UNIQUE PHYSICAL AND BIOLOGICAL
   CHARACTERISTICS
   
    * Exclusive


 * MOST EUROPEAN DOCTORS ARE OPEN TO INTEGRATED MEDICAL SOLUTIONS: DR. VINAYAK
   NAIR RADHAKRISHNAN, DIRECTOR, E5 AYURVEDA RESEARCH OG, WIEN

View More

BRAND CONNECT


AMPLIFY YOUR BRAND & BOOST YOUR BUSINESS BY CONNECTING TO RIGHT CUSTOMERS

 * Customised events
 * Thought leadership management
 * Advertorials
 * Customised reports
 * Video Series
 * Display Ads

Get in Touch


Some of our Clients





News

See whats happening in Health sector right now

Exclusive

Read and get insights from specially curated unique stories from editorial

Leaders Speak

Business leaders sharing their insights

Events

Explore and discuss challenges & trends in India's leading B2B events

Awards

Recognise work that not only stood out but was also purposeful

Webinars

Join leaders & experts for roundtables, conferences, panels and discussions


JOIN THE COMMUNITY OF 2M+ INDUSTRY PROFESSIONALS

Subscribe to our Daily Newsletter



By continuing you agree to our Privacy Policy & Terms & Conditions

Advertise With Us

We have various options to advertise with us including Events, Advertorials,
Banners, Mailers, etc.

Get in Touch

Download ETHealthworld App

Save your favourite articles with seamless reading experience



Get updates on your preferred social platform

Follow us for the latest news, insider access to events and more.



About Us

Contact Us

Newsletters

 * Guest-Post Guidelines
 * RSS Feed
 * Sitemap


THE ECONOMIC TIMES BUSINESS VERTICALS

 * Auto
 * Retail
 * Telecom
 * Energy
 * CIO
 * Real Estate
 * Marketing & Advertising
 * CFO
 * IT Security
 * BFSI
 * Government
 * Hospitality
 * HR
 * Legal
 * ET TravelWorld
 * Infra
 * B2B
 * CIOSEA
 * HRSEA
 * HRME

 * @2023 ETHealthworld.com. All Right Reserved.
 * Privacy Policy
 * Terms and Conditions